↓ Skip to main content

Dove Medical Press

Article Metrics

Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study

Overview of attention for article published in Clinical Interventions in Aging, January 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news
2 news outlets
twitter
5 tweeters

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
108 Mendeley
Title
Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer’s disease: a prospective, open-label pilot study
Published in
Clinical Interventions in Aging, January 2016
DOI 10.2147/cia.s95362
Pubmed ID
Authors

Tohru Ohnuma, Aiko Toda, Ayako Kimoto, Yuto Takebayashi, Ryoko Higashiyama, Yuko Tagata, Masanobu Ito, Tsuneyoshi Ota, Nobuto Shibata, Heii Arai

Abstract

This is the first clinical trial of this type in Japan, designed to analyze two important aspects of Alzheimer's disease (AD) management using medium-chain triglycerides. Axona was administered for 3 months (40 g of powder containing 20 g of caprylic triglycerides). We used an indurating, four-step dose-titration method (from 10 to 40 g per day) for 7 days before the trial, and examined the tolerance and adverse effects of this intervention. We also investigated its effect on cognitive function in mild-to-moderate AD patients. This was a clinical intervention in 22 Japanese patients with sporadic AD at a mild-to-moderate stage (ten females, 12 males), mean age (± standard deviation) 63.9 (±8.5) years, Mini-Mental State Examination (MMSE) score, 10-25, seven patients were ApoE4-positive. During Axona administration, we examined changes in cognitive function by obtaining MMSE and AD assessment-scale scores. Intolerance and serum ketone concentrations were also examined. The tolerance of Axona was good, without severe gastrointestinal adverse effects. Axona did not improve cognitive function in our sample of AD patients, even in those patients without the ApoE4 allele. However, some ApoE4-negative patients with baseline MMSE score ≥14 showed improvement in their cognitive functions. The modified dose-titration method, starting with a low dose of Axona, decreased gastrointestinal adverse effects in Japanese patients. Axona might be effective for some relatively mildly affected patients with AD (with cognitive function MMSE score of ≥14 and lacking the ApoE4 allele).

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 108 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Argentina 1 <1%
Unknown 107 99%

Demographic breakdown

Readers by professional status Count As %
Student > Master 19 18%
Researcher 13 12%
Student > Bachelor 9 8%
Other 8 7%
Student > Ph. D. Student 8 7%
Other 24 22%
Unknown 27 25%
Readers by discipline Count As %
Medicine and Dentistry 17 16%
Nursing and Health Professions 14 13%
Biochemistry, Genetics and Molecular Biology 10 9%
Neuroscience 10 9%
Psychology 6 6%
Other 20 19%
Unknown 31 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 October 2018.
All research outputs
#1,246,386
of 17,358,590 outputs
Outputs from Clinical Interventions in Aging
#153
of 1,598 outputs
Outputs of similar age
#30,700
of 376,058 outputs
Outputs of similar age from Clinical Interventions in Aging
#4
of 42 outputs
Altmetric has tracked 17,358,590 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,598 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.1. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 376,058 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.